PTC Therapeutics competitors, on the record

Who PTC Therapeutics names

In its own words

1. Agios Pharmaceuticals, Maze Therapeutics, Otsuka Pharmaceutical, SOM Biotech

   Word for word“Other companies are also pursuing product candidates for the treatment of PKU, including Otsuka Pharmaceutical (JNT-517), SOM Biotech (SOM-1311), Maze Therapeutics (MZE-782) and Agios Pharmaceuticals (AG-181).” 10-K for 2025

2. Alnylam Pharmaceuticals

   Word for word“Tegsedi faces competition from drugs like Onpattro (patisiran) which was launched by Alnylam Pharmaceuticals in the United States in 2018 and received approval in Brazil for the treatment of hATTR amyloidosis in 2020 as was well as AMVUTTRA (vutrisiran) which Alnylam Pharmaceuticals received approval for in the United States and Brazil in 2022 for the treatment of the polyneuropathy of hATTR amyloidosis in adults.” 10-K for 2025

3. Biogen

   Word for word“If approved, vatiquinone could face competition from Skyclarys (omaveloxolone) from Biogen, which is approved in the United States and the EU.” 10-K for 2025

4. Biohaven, NMD Pharma, Roche Pharmaceuticals, Scholar Rock

   Word for word“Other companies are also pursuing product candidates for the treatment of SMA, including Scholar Rock (apitegromab, SRK-015), Biohaven (Taldefgrobep alfa), Roche Pharmaceuticals (RO-7204239/GYM-329), Biogen / Ionis (BIIB-115/ION-306) and NMD Pharma (NMD-670).” 10-K for 2025

5. BridgeBio Pharma, Intellia Therapeutics, Proclara Biosciences

   Word for word“Other companies are also pursuing product candidates for the treatment of ATTR Amyloidosis with polyneuropathy including BridgeBio Pharma (AG 10), Intellia Therapeutics (NTLA2001), Proclara Biosciences (NPT 189) and SOM Biotech (tolcapone).” 10-K for 2025

6. Cheisi Farmaceutica, Inc.

   Word for word“Waylivra for FPL. Waylivra faces competition from Myalept (metreleptin) produced by Cheisi Farmaceutica, Inc., which is currently approved in Brazil for use in generalized lipodystrophy patients.” 10-K for 2025

7. Ionis

   Word for word“For example, Ionis is developing Olezarsen for the treatment of FCS.” 10-K for 2025

8. Larimar Therapeutics

   Word for word“There are also two assets in early development: LX-2006 (Lexeo/Frataxin AAVrh10) and CTI-1601 (Larimar Therapeutics).” 10-K for 2025

9. Novartis

   Word for word“Novartis is also developing OAV-101, an intrathecal administration of Zolgensma, for SMA patients ages ≥ 2 to < 18 years of age.” 10-K for 2025

10. Pfizer

    Word for word“Vyndaqel (tafamids meglumine) and Vyndamax (tafamidis) are commercialized in the United States, EU and some countries in Latin America by Pfizer.” 10-K for 2025

Who names PTC Therapeutics

Companies whose own annual reports name PTC Therapeutics as a competitor.

1. Biomarin Pharmaceutical names it as “PTC Therapeutics, Inc.” · 2025

   Word for word“PALYNZIQ and KUVAN face competition from an oral small molecule marketed by PTC Therapeutics,Inc., which is approved in the U.S. and EU for the treatment of PKU.” 10-K for 2025

Read from PTC Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-19. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.